Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer

International Journal of Molecular Medicine

Volumn 25, Issue 2, 2010, Pages 209-215

  Kasuya, Kazuhiko ^a,b   Shimazu, Motohide ^a   Suzuki, Minako ^b   Itoi, Takao ^b   Aoki, Tatsuya ^b   Tsuchida, Akihiko ^b  

^a TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Anti HER2; Antibody; Cancer; Cell transplantation; Stem cell like cell

Indexed keywords

CD16 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER TRANSPLANTATION; CELL DEATH; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY TEST; EMBRYO; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL TRANSPLANTATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BREAST NEOPLASMS; CELL LINE; CELL SURVIVAL; FEMALE; HUMANS; MICE; MICE, SCID; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES; STEM CELL TRANSPLANTATION; STEM CELLS; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73649094122     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000332     Document Type: Article

References (21)

1. Bargmann CI, Hung MC and Weinberg RA: The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319: 226-230, 1986.
2. Carter P, Presta L, Goman CM, et al: Humanization of an anti p185 (HER2) antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289, 1992.
3. Nishikawa M, Ozawa K, Tojo A, et al: Changes in hematopoiesis-supporting ability of C3H10T1/2 mouse embryo fibroblasts during differentiation. Blood 81: 1184-1192, 1993.
4. Steplewshi Z, Lubeck MD and Koprowski H: Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 221: 865-867, 1983.
5. Clynes RA, Towers TL, Presta LG and Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446, 2000.
6. Brown RE, Bernath AM and Lewis GO: HER-2/neu protein-receptor-positive breast carcinoma: an immunologic perspective. Ann Clin Lab Sci 30: 249-258, 2000.
7. Terada S, Matsumura K, Enosawa S, Miki M, Hoshika A, Suzuki S and Sakuragawa N: Including proliferation of human amniotic epithelial cells for cell therapy. Cell Transplant 9: 701-704, 2000.
8. Bowles JA and Weiner GJ: CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 304: 88-99, 2005.
9. Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P and Palazzo IGD: A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 53: 94-100, 1993.
10. Weiner LM, Holmes M, Richeson A, et al: Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J Immunol 151: 2877-2886, 1993.
11. Weiner LM, Clark JI, Davey MD, Li WS, Palazzo IGD, Ring BD and Alpaugh RK: Phase I trial of 2B1, a bispecific monoclonal antibody targeting FcγRIII. Cancer Res 55: 4586-4593, 1995.
12. McCall AM, Adams GP, Amoroso AR, et al: Isolation and characterization of an anti-CD16 single chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol 36: 433-446, 1999.
13. McCall AM, Shahied LS, Amoroso AR, et al: Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol 166: 6112-6117, 2001.
14. Shahied LS, Tang Y, Alpaugh K, Somer R, Greenspon D and Weiner LM: Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 279: 53907-53914, 2004.
15. Kitamura T, Koshino Y, Shibata F, Oki T, Nakajima H, Nosaka T and Kumagai H: Retrovirus-mediated gene transfer and expression cloning: Powerful tools in function genomics. Exp Hematol 31: 1007-1014, 2003.
16. Bradley TP and Bonavida B: Mechanism of cell-mediated cytotoxicity at the single cell level. IV. Natural killing and antibody-dependent cellular cytotoxicity can be mediated by the same human effector cell as determined by the two-target conjugate assay. J Immunol 129: 2260-2265, 1982.
17. Jiang M, Shi W, Zhang Q, et al: Gene therapy using adenovirus-mediated full-length anti-HER-2 antibody for HER-2 overexpression cancers. Clin Cancer Res 12: 6179-6185, 2006.
18. Studeny M, Marini FC, Dembinski JL, et al: Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96: 1593-1603, 2004.
19. Studeny M, Frank C, Champlin RE, Zompetta C, Filder IJ and Andreeff M: Bone marrow-derived mesenchemal stem cells as vehicles for interferon-β delivery into tumors. Cancer Res 62: 3603-3608, 2002.
20. Karnoub AE, Dash AB, Vo AP, et al: Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563, 2007.
21. Finkle D, Quan ZR, Asghari V, et al: HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 10: 2499-2511, 2004.